1. Home
  2. DLPN vs CANF Comparison

DLPN vs CANF Comparison

Compare DLPN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • CANF
  • Stock Information
  • Founded
  • DLPN N/A
  • CANF 1994
  • Country
  • DLPN United States
  • CANF Israel
  • Employees
  • DLPN N/A
  • CANF N/A
  • Industry
  • DLPN Other Consumer Services
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • DLPN Consumer Discretionary
  • CANF Health Care
  • Exchange
  • DLPN Nasdaq
  • CANF Nasdaq
  • Market Cap
  • DLPN 12.9M
  • CANF 14.4M
  • IPO Year
  • DLPN N/A
  • CANF N/A
  • Fundamental
  • Price
  • DLPN $1.11
  • CANF $1.32
  • Analyst Decision
  • DLPN Strong Buy
  • CANF Strong Buy
  • Analyst Count
  • DLPN 1
  • CANF 2
  • Target Price
  • DLPN $5.00
  • CANF $14.00
  • AVG Volume (30 Days)
  • DLPN 49.8K
  • CANF 1.2M
  • Earning Date
  • DLPN 11-14-2024
  • CANF 12-31-2024
  • Dividend Yield
  • DLPN N/A
  • CANF N/A
  • EPS Growth
  • DLPN N/A
  • CANF N/A
  • EPS
  • DLPN N/A
  • CANF N/A
  • Revenue
  • DLPN $51,389,626.00
  • CANF $667,000.00
  • Revenue This Year
  • DLPN $21.74
  • CANF $409.56
  • Revenue Next Year
  • DLPN $7.26
  • CANF N/A
  • P/E Ratio
  • DLPN N/A
  • CANF N/A
  • Revenue Growth
  • DLPN 21.66
  • CANF N/A
  • 52 Week Low
  • DLPN $0.95
  • CANF $1.29
  • 52 Week High
  • DLPN $3.58
  • CANF $4.69
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 45.36
  • CANF 24.83
  • Support Level
  • DLPN $1.02
  • CANF $1.50
  • Resistance Level
  • DLPN $1.20
  • CANF $1.72
  • Average True Range (ATR)
  • DLPN 0.09
  • CANF 0.20
  • MACD
  • DLPN -0.00
  • CANF -0.03
  • Stochastic Oscillator
  • DLPN 26.47
  • CANF 2.83

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: